华大智造拟溢价收购实控人旗下未盈利资产

Core Viewpoint - BGI Genomics (688114) plans to acquire 100% equity of two companies, Shenzhen BGI Sanjian Qifa Technology Co., Ltd. and Hangzhou BGI Xufeng Technology Co., Ltd., for a total of 366 million yuan, integrating cutting-edge technologies in spatial omics and nanopore sequencing into its business [1][3]. Group 1: Acquisition Details - The total acquisition price is 366 million yuan, with BGI Sanjian Qifa valued at 158 million yuan and BGI Xufeng at 208 million yuan [3]. - BGI Genomics will also inject 70 million yuan and 60 million yuan into BGI Sanjian Qifa and BGI Xufeng, respectively, to support their operations and business expansion [3][4]. - A loan of 70 million yuan will be provided to BGI Xufeng at an interest rate of 2.5% for three years to repay debts [3]. Group 2: Financial Performance - Both target companies are currently in a high-investment R&D phase and have not yet achieved profitability. BGI Sanjian Qifa reported revenues of 60.74 million yuan and 27.99 million yuan for 2024 and January-October 2025, respectively, with net losses of 11.71 million yuan and 44.98 million yuan [5]. - BGI Xufeng's revenues were 44.02 million yuan and 66.14 million yuan for the same periods, with net losses of 70.66 million yuan and 85.01 million yuan [5]. Group 3: Strategic Implications - The acquisition will enable BGI Genomics to create a comprehensive technology chain covering short-read, long-read, and spatial omics technologies, positioning it uniquely in the global market [5][6]. - The integration of these technologies is expected to enhance the company's competitive edge and profitability in the long term, with BGI Xufeng and BGI Sanjian Qifa projected to achieve profitability by 2026 and 2028, respectively [6][7]. Group 4: Valuation and Market Reaction - The valuation of BGI Sanjian Qifa shows a high appreciation rate of 2460.66%, while BGI Xufeng has a valuation increase of 296.55% [8]. - The acquisition pricing is considered reasonable compared to industry standards, with dynamic price-to-sales ratios around 3 times, significantly lower than comparable companies in their respective fields [9]. Group 5: Performance Commitments - Performance commitments have been established, with BGI Sanjian Qifa expected to achieve net profits of no less than 5 million yuan, 18.7 million yuan, and 26.4 million yuan from 2026 to 2028, totaling at least 50.1 million yuan [9]. - BGI Xufeng is expected to achieve net profits of no less than 5.2 million yuan, 24.6 million yuan, and 53 million yuan from 2028 to 2030, totaling at least 82.8 million yuan [9].